What is the prognosis for patients with myelodysplastic syndrome (MDS)?

Prognosis of Myelodysplastic Syndrome (MDS)

The prognosis of MDS is highly variable, with median overall survival ranging from 15-30 months across all risk categories and a 25-35% risk of progression to acute myeloid leukemia at 5 years, though survival can range from weeks to over 10 years depending on risk stratification. 1, 2

Overall Survival and Mortality

The natural course of MDS demonstrates extreme heterogeneity in outcomes 1:

• Median overall survival is 15-30 months when considering all MDS patients together 1, 2
• The 5-year risk of AML transformation is 25-35% across all risk groups 1, 2
• Bone marrow failure (infection and hemorrhage) is the leading cause of death, with more patients dying before overt AML develops 1
• In a large registry analysis of 2,877 deaths, 83.4% of patients with documented causes died from disease-related complications: AML transformation (46.6%), infection (27.0%), or bleeding (9.8%) 3

Risk-Stratified Survival Outcomes

The Revised International Prognostic Scoring System (IPSS-R) stratifies patients into five distinct risk groups with markedly different survival expectations 1:

Lower-Risk Disease (IPSS-R Very Low, Low, Intermediate)

• Median survival ranges from 3-10 years for lower-risk patients 2, 4
• The 5-year survival rate is approximately 68% in IPSS low-risk patients 1, 2
• Very low-risk patients have a median survival of approximately 8.8 years 5
• Approximately half of elderly lower-risk patients die from causes unrelated to MDS or AML, including cardiovascular disease and other comorbidities 5

Higher-Risk Disease (IPSS-R Intermediate, High, Very High)

• Median survival is less than 3 years for higher-risk patients 1, 4
• High-risk patients have median survival of 1.6 years 5
• Very high-risk patients have median survival of only 0.8 years 5
• Disease-related mortality predominates in higher-risk categories, with proportionally more deaths from AML transformation, infection, and bleeding 3

Critical Prognostic Factors

Three core variables drive prognosis and are incorporated into the IPSS-R: cytogenetic abnormalities, bone marrow blast percentage, and severity of cytopenias 1:

Cytogenetic Abnormalities

• Cytogenetics represent the most powerful prognostic parameter in the IPSS-R scoring system 1
• Poor-risk cytogenetics (complex karyotype, chromosome 7 abnormalities) are associated with median survival less than 5 years 2
• Favorable cytogenetics (isolated del(5q), normal karyotype) predict better outcomes 2

Bone Marrow Blast Percentage

• Higher blast percentages predict worse outcomes and faster AML progression 1
• Patients with 5-9% blasts (RAEB-1) have better prognosis than those with 10-19% blasts (RAEB-2) 1

Cytopenias

• The number and severity of cytopenias (anemia, thrombocytopenia, neutropenia) independently predict survival 1
• Low platelet count and severe anemia are particularly adverse prognostic factors 6

Additional Prognostic Factors

Patient-Related Factors

• Increasing age is an independent adverse prognostic factor beyond the IPSS-R score 1, 2, 7
• ECOG performance status independently predicts survival, with poor performance status associated with worse outcomes 1
• Comorbidities, particularly cardiovascular disease, reduce overall survival independently of MDS risk category 1, 7

Disease-Related Factors

• Red blood cell transfusion dependence predicts worse prognosis 1
• Multilineage dysplasia is associated with adverse outcomes 1
• Elevated serum ferritin (>1000 mcg/L), LDH, and β2-microglobulin predict shorter survival 1, 6
• Bone marrow fibrosis is an adverse prognostic factor, with 18% of patients with marked fibrosis progressing directly to AML 1, 8

Molecular Mutations

Somatic mutations provide additional prognostic information, though their independent impact requires further validation 1:

• Adverse prognostic mutations include: ASXL1, TP53, RUNX1, EZH2, DNMT3A, and CBL 1, 2
• TP53 mutations predict particularly poor outcomes and resistance to therapy 1
• SF3B1 mutations in MDS with ring sideroblasts predict favorable prognosis when isolated and not associated with other high-risk mutations 1
• SRSF2 and NRAS mutations are associated with increased risk of AML progression 8
• IDH1, IDH2, and NPM1 mutations are more common in patients with direct AML transformation 8

Patterns of Disease Progression

Lower-risk MDS patients follow distinct progression patterns with different outcomes 8:

• 68% of lower-risk patients remain lower-risk without progression 8
• 16.5% progress to higher-risk MDS without AML transformation 8
• 6.5% progress to higher-risk MDS and then to AML 8
• 9% progress directly from lower-risk MDS to AML 8
• 13.1% of lower-risk patients die within 2 years without disease progression, with 29.5% of documented deaths due to cytopenia-related complications 8

Impact of Treatment on Prognosis

Treatment modality significantly influences survival outcomes 1:

• Allogeneic hematopoietic cell transplantation is the only potentially curative therapy and should be evaluated at diagnosis for all higher-risk patients 2, 5, 9
• Hypomethylating agents (azacitidine, decitabine) alter disease natural history in higher-risk patients, with azacitidine extending survival by up to 74% compared to conventional care 5
• Patients with higher-risk MDS refractory to hypomethylating agents have median survival less than 6 months 5

Critical Pitfalls in Prognostic Assessment

• Do not rely solely on IPSS or IPSS-R scores; incorporate patient age, performance status, comorbidities, and transfusion dependence into prognostic assessment 1, 7
• Do not assume all lower-risk patients have indolent disease; 13% die within 2 years without progression, and specific molecular mutations (SRSF2, NRAS) predict higher progression risk 8
• Do not overlook competing causes of mortality in elderly lower-risk patients, where cardiovascular disease and infections may pose greater immediate threats than MDS progression 7, 5
• Do not delay transplant evaluation in eligible higher-risk patients, as this represents the only curative option and should be assessed at diagnosis 5, 9